BTIG analysts have revealed significant pipeline updates from MiniMed, Medtronic’s (NYSE: MDT) diabetes business. According to notes shared after a meeting with Que Dallara, soon-to-be CEO of the soon-to-be separated Diabetes unit, at the American Diabetes Association’s 85th Scientific Sessions, several developments are underway.
Medtronic plans to submit its new automated insulin delivery system, the MiniMed Flex (8 series) pump, to the FDA by the end of its fiscal year, which ends in April 2026. The company is also preparing for a label expansion of the MiniMed 780G to include type 2 diabetes.
Additionally, analysts were given a preview of the in-development MiniMed Fit patch pump, signaling Medtronic’s continued focus on expanding and innovating its diabetes care portfolio.
Follow MEDWIRE.AI for the latest updates on diabetes technology and medtech innovations.
